SEC Form 4 · accession 0001209191-17-047729
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP, CFO & COO
Period of report
Aug 2, 2017
Accepted (ET)
Aug 4, 2017 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 2, 2017 | M | 2,155 | $91.05 | A | 118,043 | D | |
| Common StockF2,F3 | Aug 2, 2017 | S | 500 | $152.49 | D | 117,543 | D | |
| Common StockF3,F4 | Aug 2, 2017 | S | 500 | $153.57 | D | 117,043 | D | |
| Common StockF3,F5 | Aug 2, 2017 | S | 700 | $154.55 | D | 116,343 | D | |
| Common StockF3,F6 | Aug 2, 2017 | S | 455 | $156.09 | D | 115,888 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $91.05 | Aug 2, 2017 | M | 2,155 | D | — | Feb 1, 2026 | Common Stock | 2,155 | 21,552 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $152.49 (range $152.00 to $152.76).
- F3Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $153.57 (range $153.08 to $154.05).
- F5Open market sales reported on this line occurred at a weighted average price of $154.55 (range $154.20 to $154.93).
- F6Open market sales reported on this line occurred at a weighted average price of $156.09 (range $155.49 to $156.40).
- F7The option vests in 16 quarterly installments from 2/2/2016.